U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939919) titled 'A Study of AK158D1 in Advanced Solid Tumors' on Nov. 01.
Brief Summary: This is a first-in-human, phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor efficacy of AK158D1 in advanced solid tumors.
Study Start Date: Nov. 16
Study Type: INTERVENTIONAL
Condition:
Solid Malignant Tumor
Intervention:
DRUG: AK158D1
Subjects will receive AK158D1 via intravenous infusion (IV) in prespecified dose levels.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Content Services with permission from Health Daily Digest....